Extract

The primary objective of the study is to determine the effect of rimonabant 20 mg daily when added to ongoing metformin therapy on glycemic control (HbA1c) over a 36 week period in patients with type 2 diabetes. Secondary objectives include evaluation of other markers of glycemic control, lipid profile, body weight, and abdominal obesity. Also, the trial will study the safety of rimonabant when added to metformin over a period of 47 weeks.

Inclusion criteria

• Diabetes Mellitus, Type 2

Country

• Indonesia
• Lithuania
• Malaysia
• Mexico
• Philippines
• Poland
• Romania
• Russian Federation
• Slovakia
• Taiwan, Province of China
• Thailand
• Ukraine
• United States

Links

• ictrp
• nct